^
Association details:
| Biomarker: | FLT3 mutation + NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors
Published date:
11/04/2020
Excerpt:
...received gilteritinib for treatment of R/R FLT3mut+ AML...co-mutations in DNMT3A, NPM1 and NRAS were observed...Patients with concurrent mutations of PM1/DNMT3A had a trend toward a higher CRc compared to FLT3 mutation alone (71% vs 50%, p= 0.2) but similar survival...
